Bryan H. King
A5084419495- Autism Spectrum Disorder Research
- Attention Deficit Hyperactivity Disorder
- Genetics and Neurodevelopmental Disorders
- Family and Disability Support Research
- Child Nutrition and Feeding Issues
- Child and Adolescent Psychosocial and Emotional Development
- Obsessive-Compulsive Spectrum Disorders
- Child Development and Digital Technology
- Behavioral and Psychological Studies
- Suicide and Self-Harm Studies
- Epigenetics and DNA Methylation
- Adolescent and Pediatric Healthcare
- Schizophrenia research and treatment
- RNA modifications and cancer
- Neurotransmitter Receptor Influence on Behavior
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- HIV Research and Treatment
- Acute Lymphoblastic Leukemia research
- Ion channel regulation and function
- Biochemical and Molecular Research
- Neuroendocrine regulation and behavior
- Infant Health and Development
- RNA and protein synthesis mechanisms
- Electroconvulsive Therapy Studies
New York University
2010-2025
University of California, San Francisco
2016-2025
Seattle Children's Hospital
2010-2023
University of Washington
2010-2023
Bunnell (United States)
2023
Seattle University
2009-2021
Memorial Sloan Kettering Cancer Center
2015-2021
St George's, University of London
2021
UCSF Benioff Children's Hospital
2017-2021
Polatis (United Kingdom)
2017
BackgroundTuberous sclerosis complex is highly variable in clinical presentation and findings. Disease manifestations continue to develop over the lifetime of an affected individual. Accurate diagnosis fundamental implementation appropriate medical surveillance treatment. Although significant advances have been made past 15 years understanding treatment tuberous complex, current diagnostic criteria not critically evaluated or updated since last consensus conference 1998.MethodsThe 2012...
Tuberous sclerosis complex is a genetic disorder affecting every organ system, but disease manifestations vary significantly among affected individuals. The diverse and varied presentations progression can be life-threatening with significant impact on cost quality of life. Current surveillance management practices are highly variable region country, reflective the fact that last consensus recommendations occurred in 1998 an updated, comprehensive standard lacking incorporates latest...
Comparative genomics allow us to search the human genome for segments that were extensively changed in last approximately 5 million years since divergence from our common ancestor with chimpanzee, but are highly conserved other species and thus likely be functional. We found 202 genomic elements vertebrates show evidence of significantly accelerated substitution rates human. These mostly non-coding DNA, often near genes associated transcription DNA binding. Resequencing confirmed five most...
<h3>Context</h3> Selective serotonin reuptake inhibitors are widely prescribed for children with autism spectrum disorders. <h3>Objectives</h3> To determine the efficacy and safety of citalopram hydrobromide therapy repetitive behavior in <h3>Design</h3> National Institutes Health–sponsored randomized controlled trial. <h3>Setting</h3> Six academic centers, including Mount Sinai School Medicine, North Shore–Long Island Jewish Health System, University Carolina at Chapel Hill, California Los...
Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disease affecting multiple body systems with wide variability in presentation. In 2013, Pediatric Neurology published articles outlining updated diagnostic criteria and recommendations for surveillance management of manifestations. Advances knowledge approvals new therapies necessitated a revision those recommendations.Chairs working group cochairs from the 2012 International TSC Consensus Group were invited to meet...
Mammalian cells possess two amino acid-sensing kinases: general control nonderepressible 2 (GCN2) and mechanistic target of rapamycin complex 1 (mTORC1). Their combined effects orchestrate cellular adaptation to acid levels, but how their activities are coordinated remains poorly understood. Here, we demonstrate an important link between GCN2 mTORC1 signaling. Upon deprivation various acids, activated up-regulates ATF4 induce expression the stress response protein Sestrin2, which is required...
OBJECTIVES: To compare 2 short-term, community caregiver training interventions for preschool-aged children with Autism Spectrum Disorder who had low resources. Low resource was defined by the US Department of Housing and Urban Development low-income index or 1 “indicator,” (eg, Medicaid eligibility). Child outcomes focused on joint engagement, attention, play. METHODS: Participants included 112 families a child met criteria being low-resourced were randomly assigned to 3-month...
Experimental studies and small clinical trials have suggested that treatment with intranasal oxytocin may reduce social impairment in persons autism spectrum disorder. Oxytocin has been administered practice to many children
Background: Although randomized clinical trials (RCTs) have investigated several treatments for social communication difficulties and repetitive behavior in autism, none has yet shown consistent superiority over placebo. Placebo response autism RCTs may impede the ability to detect meaningful treatment effects. Objective: We sought identify individual-level predictors of placebo Study Oxytocin Autism improve Reciprocal Social Behaviors (SOARS-B), a 24-week RCT intranasal oxytocin impairment...
This paper summarizes a conference held at the National Institute of Child Health and Human Development on December 6-7, 1999, self-injurious behavior [SIB] in developmental disabilities. Twenty-six top researchers U.S. from this field representing 13 different disciplines discussed environmental mechanisms, epidemiology, behavioral pharmacological intervention strategies, neurochemical substrates, genetic syndromes which SIB is prominent phenotype, neurobiological neurodevelopmental factors...
Hyperactivity, impulsiveness, and distractibility are common problems in children with autism spectrum disorder (ASD). Extended-release guanfacine is approved for attention deficit hyperactivity but not well studied ASD.In a multisite, randomized clinical trial, extended-release was compared placebo ASD accompanied by hyperactivity, distractibility.Sixty-two subjects (boys, N=53; girls, N=9; mean age=8.5 years [SD=2.25]) were randomly assigned to (N=30) or (N=32) 8 weeks. The group showed...